AR and prostate cancer: The three major non-receptor tyrosine kinases, FAK, SRC and ETK, form the SRC tyrosine kinase complex, which in prostate cancer is suggested to play an important role in the aberrant activation of the androgen receptor (AR) by phosphorylation [39].